We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Signature Test Predicts Which Tumors Will Respond to Immunotherapy

By LabMedica International staff writers
Posted on 28 Apr 2023
Print article
Image: The new discovery could improve survival of bladder cancer patients (Photo courtesy of Freepik)
Image: The new discovery could improve survival of bladder cancer patients (Photo courtesy of Freepik)

Bladder cancer is often fatal, and survival rates have not improved in the past 30 years. Although immunotherapy has revolutionized bladder cancer treatment, it has significant limitations, as most patients do not respond to the therapy. Checkpoint immunotherapy drugs, which enable the body's immune system to recognize tumors, are effective for only about 20% of bladder cancers. However, it is unclear which patients will benefit and why these drugs are not more effective for all patients. In a breakthrough that could enhance bladder cancer patients' survival, researchers have now developed a biomarker signature test to predict which tumors will be responsive to immunotherapy.

In the new study, scientists at Northwestern Medicine (Chicago, IL, USA), along with multiple international collaborators, identified three types of tumors that could respond to immunotherapy and two that could not. By employing a combination of gene expression profiling, mutations, and spatial proteomics, the researchers analyzed the non-responsive cancers to pinpoint potential new drugs and therapies that could make them responsive to immunotherapy.

In the study, investigators initiated a Phase II trial with 82 patients who received Keytruda (an immunotherapy) prior to bladder removal. This unique trial evaluated the gene expression profile before and after Keytruda treatment, enabling the researchers to fully measure the response to Keytruda when the bladder was removed. Typically, Keytruda and other immunotherapies are administered to patients with metastatic cancer, and the biological changes that occur in the tumor are not easily monitored with tumor biopsies. By profiling the transcriptome, DNA alterations, and spatial changes that took place in tumors treated with Keytruda, the investigators were able to identify the features associated with response or resistance.

"Thousands of patients have their bladder removed every year, and treating these patients with immunotherapy could improve survival and potentially increase their chance of keeping their bladder rather than having it surgically removed," said Dr. Joshua Meeks, associate professor of urology at Feinberg and a Northwestern Medicine urologist.

Related Links:
Northwestern Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.